Last reviewed · How we verify

Université du Québec à Trois-Rivières — Portfolio Competitive Intelligence Brief

Université du Québec à Trois-Rivières pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Saline Solution (NaCl 0,9%) Saline Solution (NaCl 0,9%) marketed Crystalloid fluid / Electrolyte replacement Fluid and Electrolyte Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Dalarna County Council, Sweden · 1 shared drug class
  2. Fundacion Clinica Valle del Lili · 1 shared drug class
  3. Montefiore Medical Center · 1 shared drug class
  4. Rhode Island Hospital · 1 shared drug class
  5. Rigshospitalet, Denmark · 1 shared drug class
  6. Seoul National University Hospital · 1 shared drug class
  7. Universidad Nacional de La Plata · 1 shared drug class
  8. University of Auckland, New Zealand · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Université du Québec à Trois-Rivières:

Cite this brief

Drug Landscape (2026). Université du Québec à Trois-Rivières — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universit-du-qu-bec-trois-rivi-res. Accessed 2026-05-18.

Related